Showing 109 results
-
Media Release /Eligible Canadian patients with heterozygous familial hypercholesterolemia (HeFH) are one step closer to publicly funded access to cholesterol lowering treatment.Montréal, Québec, August 21, 2025 –…
-
Media Release /• Scemblix® is first to show superior efficacy and a favourable safety and tolerability profile in a Phase III trial vs. all standard of care (SoC) therapies.1,2• …
-
Media Release /• Important milestone towards public reimbursement for a new treatment option for eligible Canadian patients living with moderate to severe hidradenitis suppurativa (HS)• …
-
Story / -
Media Release /Pluvicto® now publicly funded in provinces covering most Canadians, offering renewed hope to those facing progressive PSMA-positive metastatic castration-resistant prostate cancerMomentum builds…
-
Media Release /Despite endocrine therapy (ET), the risk of recurrence for people diagnosed with hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) early breast cancer (eBC…
